Smart-ring value doesn’t start in sapphire or sensors—it locks in at the recurring health-data subscription

Smart rings look like simple hardware: a thin shell, embedded sensing, and a battery. The supply chain reality is more like a funnel: hardware production determines whether signals are usable, but the subscription layer determines whether value is captured.

For investors, the key question is not “who makes the sapphire?” It’s “who owns the ongoing interpretation, coaching, and retention loop built on the bio-signal library gathered from real users over time.”

Oura confidentially filed for an IPO in May 2026, drawing attention to how much of its growth case rests on its member/health insights model rather than just device sales. CNBC reports the company confidentially filed the draft prospectus and highlights the subscription-driven product positioning (health and sleep tracking with ongoing insights via analytics and AI features).

Separately, the FDA has explicitly warned that smart watches and smart rings are not authorized for noninvasive blood-glucose measurement; the FDA is signaling that “signal claims” without authorization won’t become a shortcut that bypasses the evidence burden.

What looks like a single product “ring” is actually a multi-stage dependency chain. A shortage of sapphire is rarely the binding constraint; the binding constraint is whether the entire sensing-to-insights pipeline produces stable, credible longitudinal data that customers pay to keep.

FDA’s caution on unapproved smartwatch/smart-ring glucose measurement reinforces a simple economic truth: signal credibility is the gating item for medical/diabetes-adjacent scaling. In CGM, the recurring model is structurally aligned to ongoing sensing and consumables/data access—so markets tend to reward companies that can ship reliable signals repeatedly.

DexCom illustrates how that recurring-sensing logic shows up in scale: reported revenue rose from $2.91B in FY2022 to $4.66B in FY2025 (with steady gross-profit growth), implying the demand tail is sustained rather than “one device purchase.”

To keep this grounded in observable fundamentals (not device hype), we can compare how large platforms and medical-technology companies compound revenue. Apple grew revenue from $383.3B in FY2023 to $416.2B in FY2025 (FY years ending late September), underscoring that ecosystem owners can sustain large-scale distribution.

At the medical-technology adjacent layer, Medtronic grew revenue from $31.2B in FY2023 to $33.5B in FY2025 and $36.4B in FY2026—again consistent with the idea that durable healthcare ecosystems can scale without relying on a “single breakthrough sensor” to carry the whole story.